REAGAN-UDALL FOUNDATION FOR THE FDA

Advancing Drug Development by Reducing Reliance on Animal Testing

Case Example: Pre-Clinical Animal Models in Lung Toxicology

Thursday, February 26, 2026
10am - 4pm (*eastern*) | Hybrid Meeting

10am **Welcome & Opening Remarks**
Susan C. Winckler, RPh, Esq.
CEO, Reagan-Udall Foundation for the FDA

Steven Kozlowski, MD
Chief Scientist, Office of the Chief Scientist, Office of the Commissioner, FDA

10:15am **Use of Animal Models in Pre-Clinical Lung Toxicology Safety Studies: Current Expectations and Limitations**

Speakers
- Matt Reed, PhD, DABT, *Principal, Coelus, LLC*
- Jeff Tepper, PhD, DABT, *Consultant, Tepper Nonclinical Consulting*

11am **Industry Experience in Current Environment**

Speakers
- William Thelin, PhD, *Senior Vice President, Aer Therapeutics*
- Per Åberg, MSc, *Senior Director, Clinical Pharmacology and Safety Sciences, AstraZeneca*
- Jorrit Hornberg, PhD, MSc, *Vice President, Global Head of Safety Sciences, AstraZeneca*
- Aidan Curran, PhD, *Principal, Curran Nonclinical Consulting*

11:45am **Panel Discussion: Impact of Current Environment on Product Development and Patients**

Reactor Panelists
- Teresa Barnes, *Chief Executive Warrior, PF Warriors*
- Karin Hoelzer, DVM, PhD, *Senior Director, Patient Advocacy, Biotechnology Innovation Organization (BIO)*

12:30pm **Lunch**

1:15pm **Innovations in Lung Toxicology Safety Studies: New Approaches in Pre-Clinical Models & Clinical Monitoring**

Speakers

- Mary McElroy, PhD, MBA, *Head, Discovery Pharmacology and Toxicology, Charles River Laboratories*
- Alexandra Maertens, PhD, *Assistant Professor, Bloomberg School of Public Health, Johns Hopkins University*
- Megan LaFollette, PhD*, Executive Director, 3Rs Collaborative*
- Emily Richardson, PhD, *Biology Group Leader*, *CN-Bio*
- Rachel Eddy, PhD, *Imaging Scientist, Clinical Development, VIDA*
- John Fahy, MD, MSc, *Professor of Medicine, Division of Pulmonary and Critical Care Medicine, University of California-San Francisco*

2:45pm **What the Future Might Look Like: Regulatory Harmonization and Global Alignment**

Panelists

- Lorna Ewart, PhD, DSc, *Chief Scientific Officer, Emulate, Inc.*
- Andrew Goodwin, PhD, *Director, Division of Pharmacology-Toxicology for Immunology and Inflammation, FDA*
- David Jones, FRSB, FBTS, *Consultant, ApconiX*
- Tim McGovern, PhD, *Principal Consultant, White Oak Regulatory Tox, LLC*
- Steven Rowe, MD, *Chief Scientific Officer, Cystic Fibrosis Foundation*

3:55pm **Closing Remarks**

Winckler

4pm **Adjourn**